China Biopharmaceutical Announces Expanded Strategic Collaboration with GSK for Two Blockbuster Respiratory Drugs
Sino Biopharm
Pharmaceutical R&D Developer
GSK
Pharmaceutical R&D Manufacturer
CHIATAI TIANQING
High-quality pharmaceuticals research, production, and sales provider
Under the expanded agreement, CHIATAI TIANQING, a subsidiary of Sino Biopharm, will be fully responsible forFluticasone Fumeate/Vilanterol/Umeclidinium Inhalation Powder(Trelegy)、Umeclidinium Bromide and Vilanterol Inhalation Powder(Olverin)Import, distribution, hospital access, and promotional and non-promotional activities for the two products in mainland China.GSK will continue to serve as the Marketing Authorization Holder for the two drugs.（MAH）, responsible for overseeing regulatory affairs, quality control, pharmacovigilance, and global brand strategy.
Both products are blockbuster cornerstone drugs in the respiratory field,Global cumulative sales exceed$23 billion。Among them, Trelegy is currently the first and only drug in China that can be used simultaneously for asthma and chronic obstructive pulmonary disease (COPD).（COPD）Triple therapy via a single-inhaler device for maintenance treatment achieved global sales of approximately USD 4 billion in 2025, firmly securing the top position in global inhalation product sales; Anoro Ellipta, the core dual-bronchodilator regimen for COPD recommended by the GOLD guidelines, recorded global sales of approximately USD 700 million in 2025.
Historical Sales of Trelegy
Source: DXY Insight Database
Insight database shows that Sino Biopharm has cumulatively completed4 out-licensing transactions, with cumulative upfront payments exceeding$1 billion,Total Transaction Value Exceeds $7 BillionIn addition, Sino Biopharm’s network of multinational corporation (MNC) partners has further expanded; beyond GSK, it has previously established collaborations with AstraZeneca, Sanofi, Merck & Co., and Boehringer Ingelheim.